Premium
Ranibizumab for visual loss due to diabetic macular oedema
Author(s) -
Chaplin Steve,
Morphis George
Publication year - 2011
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.786
Subject(s) - medicine , ranibizumab , ophthalmology , diabetic macular edema , adverse effect , george (robot) , optometry , surgery , diabetic retinopathy , diabetes mellitus , bevacizumab , artificial intelligence , chemotherapy , endocrinology , computer science
Ranibizumab (Lucentis) has recently been licensed for the treatment of visual impairment due to diabetic macular oedema. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects and Mr George Morphis discusses its place in treatment. Copyright © 2011 Wiley Interface Ltd